PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study
Publication date: September 2026 Source: The Lancet Medical Imaging & Theranostics, Volume 1, Issue 2 Author(s): Alin Chirindel, Niklaus Schaefer, Maria del Sol Pérez Lago, Flavio Forrer, Ali Afshar-Oromieh, Stephan Beintner-Skawran, Andreas Bauman, Michael Coslovsky, Valentin Klotzbuecher, Marine Tissier, Andrea Zander, Ole Maas, Ivette Engel-Bicik, Anja Lorch, Cyrill A Rentsch, Frank Stenner, Arnoud J Templeton, Egbert Nitzsche, Damian Wild, Guillaume P Nicolas
PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. // The Lancet Medical Imaging & Theranostics. – URL: https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all
PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. The Lancet Medical Imaging & Theranostics. https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all
“PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study.” The Lancet Medical Imaging & Theranostics.
@article{article68706,
title = {PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I\&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study},
journal = {The Lancet Medical Imaging \& Theranostics},
url = {https://www.sciencedirect.com/science/article/pii/S3117452326000109?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...